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Summary Calcitriol ( la , 2 5-dihydroxy vitamin D3X applied topically in an ointment base, has been shown to be
effective in the treatment of chronic plaque psoriasis. This open study was designed to assess the 
safety and tolerability of 3 ¿¿g/g calcitriol ointment applied twice daily over treatment periods of up to 
78 weeks. In the 253 evaluable patients with chronic plaque psoriasis no clinically relevant changes 
were observed in the baseline/end-point analyses of mean serum levels of total calcium, albumin- 
adjusted total calcium, phosphorus and creatinine, and plasma calcitriol levels. Mean values of 24-h 
urinary calcium, phosphorus, creatinine and hydroxyproline excretions, creatinine clearance and 
mean urinary calcium/creatinine ratio also did not show clinically relevant changes in the baseline/ 
end-point analyses. The treatment was well tolerated, with no serious adverse events occurring 
during the course of the study. Eight patients withdrew from the study due to adverse events which, 
although not serious, were thought to be treatment-related: in seven patients skin irritation 
reactions and in one case a transient asymptomatic slight hypercalcaemia was observed, [n 
addition, assessments of global severity, global improvement and Psoriasis Area and Severity 
Index scores con firmed the therapeutic efficacy of twice daily 3 /ig/g calcitriol ointment demon­
strated in an earlier controlled study. In conclusion, this study demonstrated that twice daily 
application of 3 /ig/g calcitriol ointment is safe and well-tolerated in the treatment of chronic plaque 
psoriasis.
Calcitriol (la,25-dihydroxyvitamin D3), the endogen­
ously produced, active form of vitamin D, is important 
not only in the regulation of calcium homeostasis but 
also in skin physiology and pathophysiology. Studies 
have shown that calcitriol can inhibit proliferation and 
induce terminal differentiation of epidermal cells in
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vitro and a specific receptor for calcitriol has been 
identified on hum an epidermal keratinocytes and 
dermal fibroblasts.4 Calcitriol also exerts effects on the 
immune system.5,6 These properties of calcitriol sug­
gested that it might be useful for the clinical manage­
ment of hyperproLiferative skin disorders, and a number 
of recent clinical studies have confirmed that calcitriol, 
applied topically in an ointment base, is effective for the 
treatment of chronic plaque psoriasis,7"11 These studies 
have been relatively short-term, however, with active 
treatment of a maximum of 6 weeks, and longer studies 
are required to assess the safety and tolerability of 
calcitriol ointment as well as its efficacy in long-term 
treatment.
The aim of the study reported here was to assess the 
long-term safety, tolerability and efficacy of 3 ¿¿g/g 
calcitriol ointment, applied twice daily to skin lesions 
in patients with chronic plaque psoriasis.
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Patients and methods
Two hundred and fifty-seven out-patients with chronic 
plaque psoriasis were enrolled in this open, long-term, 
multicentre study, designed to assess the safety, toler­
ability and efficacy of twice daily application of 3 //g/g 
calcitriol ointment. All patients gave their written 
informed consent to participate in the study which 
was conducted according to the principles established 
in the Declaration of Helsinki. Ethics committee 
approval was obtained in the 20 participating centres.
Patients were selected at a screening visit and were 
excluded from the study if they were suffering from 
other types of psoriasis; had received any systemic or 
intralesional photo(chemo)therapy for psoriasis during 
the previous 2 months; had used topical psoriasis 
therapy, with the exception of emulsifying ointment 
and/or tar shampoos during the week before the start of 
therapy; were receiving any concomitant medication or 
were suffering from any diseases (including skin infec­
tions) which might interfere with the assessment of the 
efficacy, safety or tolerability of the study drugs. 
Patients were also excluded if they had known hyper­
sensitivity to vitamin D or its analogues. Women of 
child-bearing potential had to have a pregnancy test to 
rule out pregnancy prior to enrolment in the study and 
every 3 months during treatment, and were required to 
be using an effective method of contraception for the 
duration of the study.
At a screening visit the general health of the patient 
was assessed and 1 week later at the baseline visit (day 
.1) patients were provided with 3 ¡J,g/g calcitriol oint­
ment for twice daily application to all psoriatic lesions 
on the body, except those on the head. No occlusion was 
to be used, and the patients could wash off the ointment 
8 -1 2  h after application. A cut-off date was defined 18 
months after enrolment of the first patient, which 
meant that not all patients received treatment for a 
full 18 months.
Laboratory assessments of parameters reflecting
calcium and phosphorus homeostasis were performed 
at each visit. Creatinine clearance and urinary calcium/ 
creatinine ratio were calculated, in addition, in one 
centre serum levels of parathyroid hormone (PTH) and 
25-hydroxyvitamin D and urinary hydroxyproline 
excretion were also measured at baseline and end­
point. A full general health assessment was carried 
out at the final visit.
The primary efficacy variable was the overall global 
improvement rating.12 Changes in psoriatic lesions 
were scored on a six-point rating scale, at weeks 2, 4,
8, 13 up to maximally week 78 of treatment, always in 
comparison with baseline. In addition, the Psoriasis 
Area and Severity Index (PASI)13 was modified slightly 
(head not included) and scores were recorded at base­
line and at each assessment visits. Pruritus12 and 
overall global severity13,14 of the treated lesions were 
also scored. At one centre skin biopsies were taken to 
investigate how and to what extent the inflammatory, 
proliferative and differentiative components of psoriasis 
were affected by calcitriol treatment. These have been 
reported elsewhere.15
One of the objectives of this study was to assess the 
relapse rate in patients whose chronic plaque psoriasis 
had cleared or considerably improved with treatment. 
Patients reporting a relapse were asked to come to the 
clinic for assessment of the PASI score, pruritus and 
overall global severity. According to the protocol of the 
trial, only patients showing a relapse within 3 months 
could re-enter the study.
The non-parametric, two-sided Wilcoxon signed- 
rank test was used to compare baseline safety (labora­
tory and vital signs) data with the end-point data.
Results
Four of the 257 patients who entered the study had 
neither safety nor efficacy data after receiving study 
medication and were excluded from all analyses. Demo­
graphic data and disease details of the 253 evaluable
Males (ii -  155) Females (n =  98) Total (ii =  253)
Characteristic mean ±  SD mean ±  SD mean ±  SD
Age (years) 42*4 ±  12*4 41-5 ± 1 3 - 7 42-1 ±  12*9
Weight (kg) 81-7 ±  12*9 67*1 ±  14-4 76-0 ±  15-2
Height (cm) 176*4 =h 6-9 163-1 ± 7 * 5 171-3 ± 9 - 6
History of psoriasis (months) 197-8 ±  142*7 211-1 ±  136-9 202-9 ±  140-4
Total body surface area involved (%) 14*8 ±  15-3 12-7 ±  12*4 14-0 ±  14-2
/!, number of patients. 
SO, standard deviation.
Table 1. Demographic data and disease 
characteristics of evaluable patients
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patients are summarized in Table 1. A total of 219 
patients were treated continuously for at least 3 
months, 149 for at least 6 months, 75 patients for at 
least 12 months and 16 patients for at least 18 months.
Forty-six patients (18%) withdrew from the study 
prematurely because their psoriasis improved or 
cleared, seven (2*8%) withdrew due to local intoler­
ance and one (0-4%) due to hypercalcaemia. One 
hundred and eight patients (42-7%) were withdrawn 
due to lack of efficacy. However, included in this 
relatively high figure were patients who showed 
improvement during the first weeks or months of 
treatment but then showed no further Improvement 
or some deterioration upon continued treatment. (This 
is not uncommon in long-term studies of this type.)
The actual amount of ointment applied was depen­
dent on the size of the lesions and the thickness of the 
applied layer of ointment. Patients were asked to return 
all tubes at the end of the study. Of the 80 patients who 
returned all tubes dispensed, the mean quantity of 
ointment used was 6 g/day (range l-24g /day). 
Twenty-four patients (30% of those patients who 
returned all tubes) used more than 1000 g calcitriol 
ointment and eight (10%) more than 2000 g during 
their treatment period. Five patients (6%) used on 
average more than 15 g ointment daily, while 13 
patients (16%) used more than 10 g daily.
No serious adverse events or deaths occurred during 
the course of the study. Fifteen per cent of patients 
experienced a transient skin irritation reaction at some 
time. These reactions were generally mild. Eight 
patients withdrew from the study due to adverse 
events which, though not serious, were thought to be 
related to the study medication. Seven of these were 
considered to be skin irritation reactions and one 
patient developed a transient, asymptomatic slight 
hypercalcaemia.
No statistically significant and clinically relevant
Tabic 2. Blood biochemistry: bascline/end-point analyses
changes were observed in the baseline/end-point 
analyses of any laboratory parameter. Blood bio­
chemistry baseline/end-point analyses for calcium, 
albumin-adjusted calcium, phosphorus, creatinine, cal­
citriol, PTH and 25-hydroxyvitamin D are summarized 
in Table 2. The mean values of 24-h urinary calcium, 
phosphorus, creatinine and hydroxyproline excretion, 
urinary calcium/creatinine ratio and creatinine clear­
ance did not show clinically relevant changes in the 
baseline/end-point analyses. The mean systolic/ 
diastolic blood pressure and mean pulse rate also 
remained well within the normal range throughout 
the study and baseline/end-point analysis did not 
reveal any clinically relevant changes in these 
parameters.
Ninety-six (40*1%) patients showed definite or con­
siderable improvement at end-point compared with 
baseline, and clearance of psoriasis was reported in 
39 (16*3%) patients. Forty-six patients who showed 
clearing or considerable improvement of psoriasis 
were withdrawn from the study due to this outcome. 
Eleven (23%) of these patients relapsed within 3 months 
and subsequently re-entered the study. From the 
remaining group of 36 patients, a relapse after 3 
months was reported in six patients, and they were 
subsequently also re-entered into the study (although 
this should be considered a protocol violation).
The number of patients with severe or very severe 
psoriasis fell from 120 (47-4%) at baseline to 54 
(21*4%) at end-point, while the number with none or 
slight psoriasis increased from 19 (7*5%) to 98 (38*8%).
IPruritus " showed a significant improvement over the 
course of the study. At baseline, 4*3% of the patients 
complained of severe, distressing pruritus, which had 
fallen to 1*2% at the 3- and 12-month assessments. At 
the start of the study, only 17% of patients had no 
specific complaint of pruritus, but this had improved 
to 48-4% at the 3-month assessment and 38*7% at
Parameter n
Baseline 
mean ±  SD n
End-point 
mean ~  SD F- va lue
Calcium— total (mmol/I) 247 2-353 ±  0-108 2 2 4 2*343 ± 0 - 1 1 2 0-5 0 16
Calcium— total adjusted (mmol/1) 244 2-222 ±  0-112 223 2*216 ±  0*119 0-3795
Phosphorus (mmol/1) 238 1-137 ±  0-193 222 M 1 4 ±  V203 0 -4 0 6 4
Calcitriol (pg/ml) 228 40-29 ±  15-62 250 4 2 1 2  ± 1 7 - 1 4 0-1042
2 5-hydroxyviLamin D3 /.¿g/1) 26 134-69 ±  50-32 30 1 2 2 - 9 7  ±  56-31 0 -1 6 19
Parathyroid hormone (pmol/I) 31 0-332 ± 0 - 1 1 5 31 0-325  ± 0 - 1 2 0 0 -5 5 0 0
n, number of patients. 
SD, standard deviation.
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Table 3. Psoriasis Area and Severity Index (PASI) score
Assessment time n Absolute score Percentage reduction
Baseline 253 9-71
3 months 253 4-24 53’24
1 2 months 180 4*23 54-28
.18 months 26 4*08 59-59
End-point 253 4*32 51*24
n, number of patients.
end-point. The PASI score16 showed a marked improve­
ment after 3 months treatm ent (53-2% reduction in 
score), which was maintained over the whole course of 
the study (see Table 3).
D iscussion
Twice daily application of 3 ¿¿g/g calcitriol ointment for 
up to 78 weeks had no clinically relevant effects on 
calcium and phosphorus homeostasis and renal func­
tion in this large group of patients with chronic plaque 
psoriasis. These results confirm and extend the findings7 t 7of previously reported short-term studies ’ and they 
appear to refute suggestions that topical calcitriol 
treatm ent may be unsafe due to unwanted effects on 
systemic calcium homeostasis. For, even in patients 
who used large quantities of the ointment for many 
months, no noteworthy changes were seen in serum 
total calcium levels or urinary calcium excretion.
The treatment was generally very well tolerated and 
there were no reports of serious adverse events. It is an 
important advance of antipsoriatic therapy that vitamin 
D3 analogues permit safe long-term management of 
psoriasis over many months. In a previous study 
involving 161 patients treated for up to 1 year, an 
ointment containing the synthetic vitamin D3 ana­
logue, calcipotriol (50 ¿¿g/g), also proved to be safe 
and well tolerated.18 In the present study the rate of 
withdrawal due to treatment-associated local intoler­
ance was 2'8% (seven of 253 patients), while in the 
long-term study with calcipotriol18 5*6% (nine of 161) 
of patients had to discontinue treatment due to irritation.
The open design of this study means that no firm 
conclusions can be drawn as to the long-term efficacy of 
twice daily 3 ¡1 g/g calcitriol ointment in chronic plaque 
psoriasis. The results obtained for the assessments of the 
global improvement scale, the PASI score and the global 
severity scale appear, however, to confirm the thera­
peutic efficacy demonstrated in an earlier controlled 
study, which used this regimen for up to 6 weeks.8
From the 47 patients who qualified to enter the 
relapse phase of the study, 11 (23%) relapsed within 3 
months, and a relapse was reported in a further six 
patients after 3 months. This relapse rate is considerably 
lower than that observed after topical corticosteroid 
therapy,19 and the possible mechanisms involved war­
rant further investigation.
In conclusion, this open study demonstrated that 
twice daily application of 3 /¿g/g calcitriol ointment is 
safe and well tolerated in the long-term treatment of 
chronic plaque psoriasis.
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